Хроническая HCV-инфекция: взгляд интерниста (I часть)


Цитировать

Полный текст

Аннотация

Аннотация Инфицирование вирусом гепатита С (HCV) приводит к развитию не только хронического гепатита с последующими осложнениями в виде цирроза печени и гепатоцеллюлярной карциномы, но и значительного числа других заболеваний — так называемых внепеченочных проявлений хронической HCV-инфекции. Это объясняется как гепато-, так и лимфотропностью вируса. Наиболее ярким примером такого течения хронической HCV-инфекции, при котором происходит сочетание инфекционно-воспалительного процесса с аутоиммунными расстройствами и онкогенезом, служат смешанная криоглобулинемия и В-клеточная не-Ходжкинская лимфома. В основе патогенеза этих патологических состояний лежит клональная экспансия В-лимфоцитов, возникающая в условиях их продолжительной стимуляции вирусом или вирусными белками. Первая часть настоящего обзора посвящена анализу связи хронической HCV-инфекции с развитием лимфопролиферативных и аутоиммунных расстройств, а также ассоциации с поражением почек.

Об авторах

М Л Зубкин

Московский НИИ эпидемиологии и микробиологии им. Г.Н. Габричевского Роспотребнадзора; Филиал Военно-медицинской академии им. С.М. Кирова, Москва

В И Червинко

Филиал Военно-медицинской академии им. С.М. Кирова

Москва, Россия

Ю В Овчинников

Филиал Военно-медицинской академии им. С.М. Кирова

Москва, Россия

Е В Крюков

Главный военный клинический госпиталь им. Н.Н. Бурденко

Москва, Россия

О Н Котенко

Городская клиническая больница №52 Департамента здравоохранения Москвы

Москва, Россия

Список литературы

  1. Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis. 1990;162(2):569-570. doi: 10.1093/infdis/162.2.569
  2. Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Digestive Liver Dis. 2007;39(1):38-45. doi: 10.1016/S1590-8658(07)80009-0
  3. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008;134(3):812-822. doi: 10.1053/j.gastro.2007.12.011
  4. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, Antonelli A, Zignego AL. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015;7(3):327-343. doi: 10.4254/wjh.v7.i3.327
  5. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Reviews in basic and clinical gastroenterology and hepatology. Gastroenterology. 2015;49(6):1345-1360. doi: 10.1053/j.gastro.2015.08.035
  6. Zignego AL, Gragnani L, Piluso А, Sebastiani M, Giuggioli D, Fallahi P, Antonelli A., Ferri C. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol. 2015;11(1):15-31. doi: 10.1586/1744666X.2015.997214
  7. Ferri C., Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Digestive Liver Dis. 2007;39(1):13-21. doi: 10.1016/S1590-8658(07)80005-3
  8. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469-477. doi: 10.1093/infdis/jis385
  9. Maruyama S, Koda Ma, Oyake N, Sato H, Fujii Y,Horie Y, Murawaki Y. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58(1):11-15. doi: 10.1016/j.jhep.2012.07.045
  10. Brouet JC, Clauvel JP, Danon F, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-788. doi: 10.1016/0002-9343(74)90852-3
  11. Terrier B, Karras A, Kahn JE, Le Guenno G, Marie I, Benarous L, Lacraz A, Diot E, Hermine O, de Saint-Martin L, Cathébras P, Leblond V, Modiano P, Léger JM, Mariette X, Senet P, Plaisier E, Saadoun D, Cacoub P. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore) 2013;92(2):61-68. doi: 10.1097/MD.0b013e318288925c
  12. Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North America. 2015;41(1):93-108. doi: 10.1016/j.rdc.2014.09.008
  13. Saadoun D, Thibault V, Si Ahmed SN, Alric LMallet M, Guillaud C, Izzedine H, Plaisier A, Fontaine H, Costopoulos MLe Garff-Tavernier M, Hezode C, Pol S, Musset L, Poynard T, Cacoub P. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2015;0:1-6. doi: 10.1136/annrheumdis-2015-208339
  14. Dammacco F, Racanelli V, Russi S, Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exper Med. 2016;1-10. doi: 10.1007/s10238-016-0410-9
  15. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. New Engl J Med. 2013; 369(11):1035-1045. doi: 10.1056/NEJMra1208642
  16. Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997;25(5):1237-1244. doi: 10.1002/hep.510250529
  17. Mariotto S, Ferrari S, Monaco S. HCV-related central and peripheral nervous system demyelinating disorders. Inflammation Allergy Drug Targets. 2014;13:299-304. doi: 10.2174/1871528113666140908113841
  18. Gupta A, Quigg RJ. Glomerular Diseases Associated With Hepatitis B and C. Advances Chron Kidney Dis. 2015;22(5):343-351. doi: 10.1053/j.ackd.2015.06.003
  19. Barsoum RS. Hepatitis C virus: from entry to renal injury — facts and potentials. Nephrol Dial Transplant. 2007;22(7):1840-1848. doi: 10.1093/ndt/gfm205
  20. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia — a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966;40(6):837-856. doi: 10.1016/0002-9343(66)90200-2
  21. Retamozo S, Diaz-Lagares C, Bosch X, Bove A, Brito-Zeron P, Gomez ME, Yagüe J, Forns X, Cid MC, Ramos-Casals M. Lifethreatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013;92(5):273-284. doi: 10.1097/MD.0b013e3182a5cf71
  22. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis.Am J Med. 2015;128(9):950-955. doi: 10.1016/j.amjmed.2015.02.017
  23. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017-1029. doi: 10.1016/j.cgh.2010.08.026
  24. МухинН.А., КозловскаяЛ.В., МалышкоЕ.Ю. Криоглобулинемическийнефрит, ассоциированныйсхроническойинфекциейвирусагепатитаС. Терапевтическийархив. 2000;6:1-5.
  25. Tampaki M, Koskinas J. Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J Gastroenterol. 2014:20(35):12372-12380. doi: 10.3748/wjg.v20.i35.12372
  26. КозловскаяЛ.В, ТэгайС.В., МалышкоЕ.Ю., ЛопаткинаТ.Н., КосминковаЕ.Н. Поражениепочек, ассоциированноесвирусамигепатитовВиС. Consilium Med. 2002;4(7):337-341.
  27. Лысенко Л.В., Гордовская Н.Б., Коротчаева Ю.В. «Диагностика и лечение нефрита при HBV и HCV инфекции, включая нефрит при криоглобулинемическом васкулите». Национальные клинические рекомендации по лечению гломерулонефритов. Под редакцией Шилова Е.М. Сборник клинических рекомендаций. М.: Белыйветер; 2015.
  28. Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815-1827. doi: 10.1517/14656566.2015.1066333
  29. Ferri C, Antonelli A, Sebastiani M, Colaci M, Zignego AL. The expanding spectrum of clinical features in HCV-related mixed cryoglobulinemia. In: Dammacco F, editor. HCV infection and cryoglobulinemia. Milan: Springer-Verlag Italia; 2012.
  30. Милованова С.Ю., Козловская Л.В., Гордовская К.Б. Полиморфизм клинических проявлений криоглобулинемического васкулита, ассоциированного с хроническим гепатитом С. Альманах клинической медицины. 2014;30:46-51.
  31. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25. doi: 10.1186/1750-1172-3-25
  32. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748-1757. doi: 10.1002/art.30319
  33. Gragnani L. Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, Stasi C, Ranieri J, Monti M, Arena U, Iannacone C, Laffi G, Zignego AL Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.Hepatology. 2015;61(4):1145-1153. doi: 10.1002/hep.27623
  34. Dаmmacco F. Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiт MA, Chironna M, Sansonno D. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-353. doi: 10.1182/blood-2009-10-245878
  35. Мухин Н.А., Козловская Л.В., Милованова Л.Ю., Тэгай С.В., Гордовская Н.Б., Игнатова Т.М., Кудлинский И.С. HCV-ассоциированный криоглобулинемический васкулит с тяжелым поражением почек и развитием В-клеточной лимфомы. Современные возможности изменения прогноза с помощью моноклональных антител к CD20 и противовирусной терапии Клиническая нефрология. 2011;2:61-69.
  36. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis. 2014;73(9):e58. doi: 10.1136/annrheumdis-2014-205997
  37. Saadoun D Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-334. doi: 10.1182/blood-2009-10-248518
  38. Terrier ВSaadoun D, Sène D, Sellam J, Pérard L, Coppéré B, Karras A, Blanc F, Buchler M, Plaisier E, Ghillani P, Rosenzwajg M, Cacoub P. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531-2540. doi: 10.1002/art.24703
  39. Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, Mitrevski M, Ranieri J, Fognani E, Piluso A, Granata M, De Silvestri A, Scotti V, Mondelli MU, Zignego AL, Fiorilli M, Casato M. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmunity Revi. 2015;14(10):889-896. doi: 10.1016/j.autrev.2015.05.013
  40. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadiй M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A.. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008;6(4):451-458. doi: 10.1016/j.cgh.2008.02.011
  41. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, Pietrogrande M, Renoldi P, Bombardieri S, Bordin G. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995;88(2):115-126.
  42. Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: a 15-year prospective study. Medicine (Baltimore). 2013;92(5): 245-256. doi: 10.1097/MD.0b013e31829d2abc
  43. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117(6):1792-1798. doi: 10.1182/blood-2010-06-275818
  44. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034-1041. doi: 10.1016/j.amjmed.2007.06.022
  45. De Re V, Caggiari L, Simula MP, De Vita S, Mazzaro C, Lenzi M, Massimo GM, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Talamini R, Spina M, Tirelli U, Cannizzaro R, Dolcetti R. Role of the HLA class II: HCV-related disorders. Ann New York Academy of Sciences. 2007;1107:308-318. doi: 10.1196/annals.1381.033
  46. Fognani E, Giannini C, Piluso A, Gragnani L, Monti M, Caini P, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One. 2013;8(5):e62965. doi: 10.1371/journal.pone.0062965
  47. Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, Bridger C, Vergani D, Bianchi FB, Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 1991;338(8762):277-280. doi: 10.1016/0140-6736(91)90418-O
  48. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723-1732. doi: 10.1053/j.gastro.2003.09.025
  49. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010-2017. doi: 10.1001/jama.297.18.2010
  50. Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55(2):634-641. doi: 10.1002/hep.25499
  51. Paydas S. Hepatitis C virus and lymphoma. Critical Rev Oncol/Hematol. 2015;93(3):246-56. doi: 10.1016/j.critrevonc.2014.10.008
  52. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi ME, Di Pietro E, La Villa G, Laffi G, Gentilini P. Prevalence of bcl-2 rearrangement in patients with hepatitis C virusrelated mixed cryoglobulinemia with or without B-cell lymphomas. Ann Int Med. 2002;137(7):571-580. doi: 10.7326/0003-4819-137-7-200210010-00008
  53. Forghieri F, Luppi M, Barozzi P, Maffei R, Potenza L, Narni F, Marasca R. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Development Immunol. 2012;2012:1-9. doi: 10.1155/2012/807351
  54. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169-177. doi: 10.1016/j.jhep.2013.03.018
  55. Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Int Med. 2006;166(19):2101-2108. doi: 10.1001/archinte.166.19.2101
  56. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696-3706. doi: 10.1002/art.22168
  57. Hermine O, Lefrиre F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. New Engl J Med. 2002;347(4):89-94. doi: 10.1056/NEJMoa013376
  58. Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol. 2009;145(2):255-257. doi: 10.1111/j.1365-2141.2008.07565.x
  59. Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d’Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404-1410. doi: 10.1093/annonc/mdu166
  60. Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C. ANRS HC-13 Lympho-C Study Group Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90:197-203. doi: 10.1002/ajh.23889
  61. La Mura V, De Renzo A, Perna F, D’Agostino D, Masarone M, Romano M, Bruno S, Torella R, Persico M.. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49(4):557-563. doi: 10.1016/j.jhep.2008.06.025
  62. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Digest Dis Scie. 2015;60(12):3801-3813. doi: 10.1007/s10620-015-3801-y
  63. McGuire BM, Julian BA, Bynon JS, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Int Med. 2006;144(10):735-741. doi: 10.7326/0003-4819-144-10-200605160-00007
  64. Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16(12):1815-1827. doi: 10.1517/14656566.2015.1066333
  65. Ozkok A, Yildiz A. Hepatitis c virus associated glomerulopathies. World J Gastroenterol. 2014;20(24):7544-7554. doi: 10.3748/wjg.v20.i24.7544
  66. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008;109:1-99. doi: 10.1038/ki.2008.81
  67. Kasuno K, Ono T, Matsumori A, Nogaki F, Kusano H, Watanabe H, Yodoi J, Muso E. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis. 2003;41(4):767-775. doi: 10.1016/S0272-6386(03)00024-6
  68. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36(6):1439-1445. doi: 10.1053/jhep.2002.37191
  69. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Society Nephrol. 2009;4(1):207-220. doi: 10.2215/CJN.03710708
  70. Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10(3):415-423. doi: 10.1007/s12072-015-9684-3
  71. Appel GB. Membranoprolferative glomerulonephritis — mechanisms and treatment. Contributions Nephrol. 2013;181:163-174. doi: 10.1159/000348635
  72. Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nature Rev Nephrol. 2015;11(1):14-22. doi: 10.1038/nrneph.2014.217
  73. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Kobayashi M, Kumada H. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Int Med. 1998;37(10):836-840. doi: 10.2169/internalmedicine.37.836
  74. Ji F, Li Z, Ge H, Deng H. Successful interferon-б treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Int Med. 2010;49(22):2531-2532. doi: 10.2169/internalmedicine.49.4365
  75. Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013;23(2):143-145. doi: 10.4103/0971-4065.109443
  76. Morales JM, Pascual-Capdevila J, Campistol JM, Fernandez-Zatarain G, Muñoz MA, Andres A, Praga M, Martinez MA, Usera G, Fuertes A, Oppenheimer F, Artal P, Darnell A, Rodicio JL. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63(11):1634-1639. doi: 10.1097/00007890-199706150-00017
  77. Cheng Z, Zhou B, Shi X, Zhang Y, Zhang L, Chen L, Liu X. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chinese Med J (Engl). 2014;127(7):1206-1210.
  78. Stehman-Breen C, Alpers C, Fleet W, Fleet WP, Johnson RJ. Focal segmental sclerosis among patients infected with HCV. Nephron. 1999;81(1):37-40. doi: 10.1159/000045243
  79. Guerra G, Narayan G, Rennke HG, Jaber BL. Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection. Clin Nephrol. 2003;60:364-368. doi: 10.5414/CNP60364
  80. Fabrizi F, Bruchfeld A, Mangano S, Dixit V, Messa P, Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artificial Organs. 2007;30(3):212-219. doi: 10.1111/j.1365-2893.2007.00907.x

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах